We use cookies to improve your experience. See our Privacy Policy.
NRX Pharmaceuticals, Inc. is a pharmaceutical preparations company incorporated in DE, trading on the Nasdaq.
Brefyr has analyzed 1 SEC filing for NRXP, with the most recent being a DEF 14A filed on November 5, 2026. Each filing is scored for significance on a 1-10 scale to help investors quickly identify the most important disclosures.
Exchange
Nasdaq
Sector
Healthcare
Filer Category
Non-accelerated filer<br>Smaller reporting company
Fiscal Year End
December
| Date | Type | Significance | Details |
|---|---|---|---|
| Nov 5, 26 | DEF 14A | Routine (0/10) | View |
NRX Pharmaceuticals, Inc. is a pharmaceutical preparations company incorporated in DE, trading on the Nasdaq.
Brefyr has analyzed 1 SEC filing for NRXP, including DEF 14A. The most recent filing was a DEF 14A filed on November 5, 2026.
No recent insider transactions have been detected in NRXP SEC filings.
NRX Pharmaceuticals, Inc. is incorporated in DE and is classified as a Non-accelerated filer<br>Smaller reporting company filer with the SEC.
NRX Pharmaceuticals, Inc.'s fiscal year ends in December. Annual 10-K reports are typically filed within 60-90 days after the fiscal year end.
Last updated: November 5, 2026
Data sourced from SEC EDGAR public filings. For informational purposes only — not investment advice. AI-generated summaries may contain errors. See our full disclaimer.